Successful use of ketamine to treat severe depression with suicidality post-COVID-19 – A case report

Every second patient who suffers from COVID-19 experiences is at risk for depression. The treatment of severe depression with suicidal risk is challenging in patients with COVID-19 given the restrictions in access to and safety concerns with the use of electroconvulsive therapy during the COVID pand...

Descripción completa

Detalles Bibliográficos
Autores principales: Meha, Sharma, Suhas, Satish, Rao, Naren P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier B.V. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800325/
https://www.ncbi.nlm.nih.gov/pubmed/36597498
http://dx.doi.org/10.1016/j.psycr.2022.100100
_version_ 1784861272241602560
author Meha, Sharma
Suhas, Satish
Rao, Naren P
author_facet Meha, Sharma
Suhas, Satish
Rao, Naren P
author_sort Meha, Sharma
collection PubMed
description Every second patient who suffers from COVID-19 experiences is at risk for depression. The treatment of severe depression with suicidal risk is challenging in patients with COVID-19 given the restrictions in access to and safety concerns with the use of electroconvulsive therapy during the COVID pandemic. Although ketamine is effective in treating depression, especially in presence of acute suicidality, to date, there are no reports on ketamine use to treat severe depression in the context of COVID-19. In this case report, we describe the success of ketamine to treat a person with severe depression and suicidality following COVID-19 infection.
format Online
Article
Text
id pubmed-9800325
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Author(s). Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-98003252022-12-30 Successful use of ketamine to treat severe depression with suicidality post-COVID-19 – A case report Meha, Sharma Suhas, Satish Rao, Naren P Psychiatry Res Case Rep Article Every second patient who suffers from COVID-19 experiences is at risk for depression. The treatment of severe depression with suicidal risk is challenging in patients with COVID-19 given the restrictions in access to and safety concerns with the use of electroconvulsive therapy during the COVID pandemic. Although ketamine is effective in treating depression, especially in presence of acute suicidality, to date, there are no reports on ketamine use to treat severe depression in the context of COVID-19. In this case report, we describe the success of ketamine to treat a person with severe depression and suicidality following COVID-19 infection. The Author(s). Published by Elsevier B.V. 2023-06 2022-12-30 /pmc/articles/PMC9800325/ /pubmed/36597498 http://dx.doi.org/10.1016/j.psycr.2022.100100 Text en © 2022 The Author(s). Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Meha, Sharma
Suhas, Satish
Rao, Naren P
Successful use of ketamine to treat severe depression with suicidality post-COVID-19 – A case report
title Successful use of ketamine to treat severe depression with suicidality post-COVID-19 – A case report
title_full Successful use of ketamine to treat severe depression with suicidality post-COVID-19 – A case report
title_fullStr Successful use of ketamine to treat severe depression with suicidality post-COVID-19 – A case report
title_full_unstemmed Successful use of ketamine to treat severe depression with suicidality post-COVID-19 – A case report
title_short Successful use of ketamine to treat severe depression with suicidality post-COVID-19 – A case report
title_sort successful use of ketamine to treat severe depression with suicidality post-covid-19 – a case report
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800325/
https://www.ncbi.nlm.nih.gov/pubmed/36597498
http://dx.doi.org/10.1016/j.psycr.2022.100100
work_keys_str_mv AT mehasharma successfuluseofketaminetotreatseveredepressionwithsuicidalitypostcovid19acasereport
AT suhassatish successfuluseofketaminetotreatseveredepressionwithsuicidalitypostcovid19acasereport
AT raonarenp successfuluseofketaminetotreatseveredepressionwithsuicidalitypostcovid19acasereport

Ejemplares similares